Background illustration for clinical trials search

Pancreatic Cancer Clinical Trials

Browse 1,722 pancreatic cancer clinical trials enrolling across the United States and Canada. Search by city or state to find one near you.

Filter
1

Ultra-High Resolution Optical Coherence Tomography in Detecting Micrometer Sized Early Stage Pancreatic Cancer in Participants With Pancreatic Cancer

for
Pancreatic Carcinoma,
Location: Columbus OH
Sponsor: Ohio State University Comprehensive Cancer Center

Sex: All

Age: 18+

Code: NCT03711890

Recruiting

Testing Higher Dose Radiation Therapy for Locally Advanced Pancreatic Cancer

for
Locally Advanced Unresectable Pancreatic Ductal Adenocarcinoma,
Location: Bath ME, Portland ME, Scarborough ME, South Portland ME,
Sponsor: NRG Oncology

Sex: All

Age: 18+

Code: NCT06958328

Phase 3, Recruiting

Study of Zoldonrasib + Chemo of Investigator's Choice vs Placebo + Chemo of Investigator's Choice as First-line Treatment in Metastatic KRAS G12D-mutated Pancreatic Adenocarcinoma ( RASolute 305 )

for
Pancreatic Cancer, Pancreatic Cancer Metastatic, PDAC,
Location: Boston MA, New Haven CT, New York NY, East Brunswick NJ,
Sponsor: Revolution Medicines, Inc.

Sex: All

Age: 18+

Code: NCT07621718

Phase 3, Recruiting

Artidis Nanomechanical Signature Profiling of Pancreatic Cancer Specimens

for
Pancreatic Cancer, Pancreatic Neoplasms,
Location: Tampa FL
Sponsor: ARTIDIS AG

Sex: All

Age: 18+

Code: NCT07542041

Recruiting

Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients

for
PDAC, PDAC - Pancreatic Ductal Adenocarcinoma, NSCLC,
Location: Boston MA, New York NY, Washington D.C. DC, Fairfax VA,
Sponsor: Tango Therapeutics, Inc.

Sex: All

Age: 18+

Code: NCT06922591

Phase 1, Phase 2, Recruiting

Interested in new trials?

Get alerts for new trials in your area by subscribing now

Subscriber Image

Pancreatic Cancer and Synchronous Liver Metastases Resection Following Neoadjuvant FOLFIRINOX

for
Pancreas Adenocarcinoma, Pancreas Metastases, Pancreas Cancer
Location: Quebec City
Sponsor: Laval University

Sex: All

Age: 18+

Code: NCT06349278

Recruiting

Study of Nab-Paclitaxel and Gemcitabine With or Without SBP-101 in Pancreatic Cancer

for
Pancreatic Cancer Metastatic, Pancreatic Ductal Adenocarcinoma,
Location: New Haven CT, New York NY, Rochester NY, Detroit MI,
Sponsor: Panbela Therapeutics, Inc.

Sex: All

Age: 18+

Code: NCT05254171

Phase 2, Phase 3, Recruiting

Testing the Combination of Two Approved Chemotherapy Drugs and Radiation Prior to Surgery in Localized Pancreatic Cancer

for
Pancreas Adenocarcinoma, Resectable Pancreatic Cancer
Location: Loma Linda CA
Sponsor: Loma Linda University

Sex: All

Age: 18+

Code: NCT03492671

Phase 2, Recruiting

A Phase 2 Study of siG12D LODER in Combination With Chemotherapy in Patients With Locally Advanced Pancreatic Cancer

for
Pancreatic Ductal Adenocarcinoma, Pancreatic Cancer
Location: New York NY, Houston TX
Sponsor: Silenseed Ltd

Sex: All

Age: 18+

Code: NCT01676259

Phase 2, Recruiting

APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation

for
Pancreatic Acinar Cell Carcinoma,
Location: Saint Johnsbury VT, Lebanon NH, Commack NY,
Sponsor: National Cancer Institute (NCI)

Sex: All

Age: 18+

Code: NCT04858334

Phase 2, Recruiting

Th-1 Dendritic Cell Immunotherapy Plus Standard Chemotherapy for Pancreatic Adenocarcinoma

for
Pancreatic Adenocarcinoma, Pancreatic Cancer,
Location: Houston TX
Sponsor: Diakonos Oncology Corporation

Sex: All

Age: 18+

Code: NCT04157127

Phase 1, Recruiting
New

Chemotherapy With or Without IMD10 (Focused Ultrasound) in the Treatment of Borderline Resectable or Locally Advanced Pancreatic Cancer

for
Pancreatic Cancer, Borderline Resectable Pancreatic Cancer,
Location: Charlottesville VA
Sponsor: IMGT Co., Ltd.

Sex: All

Age: 18 - 70+

Code: NCT07325214

Recruiting
New

A Study of Standard of Care Drugs With or Without Ivermectin for Daraxonrasib-Induced Skin Toxicity in People With Pancreatic Cancer

for
Pancreatic Cancer, Skin Toxicities
Location: Commack NY, Uniondale NY, Harrison NY, New York NY,
Sponsor: Memorial Sloan Kettering Cancer Center

Sex: All

Age: 18+

Code: NCT07895498

Phase 2, Recruiting

Radiotherapy With Chemotherapy as Neoadjuvant Therapy of Resectable and Borderline Resectable Pancreas Cancer

for
Pancreatic Cancer
Location: Charlottesville VA
Sponsor: University of Virginia

Sex: All

Age: 18+

Code: NCT01333332

Phase 2, Recruiting

PurIST Classification-Guided Adaptive Neoadjuvant Chemotherapy by RNA Expression Profiling of EUS Aspiration Samples

for
Pancreatic Cancer
Location: Milwaukee WI, Scottsdale AZ
Sponsor: Medical College of Wisconsin

Sex: All

Age: 18+

Code: NCT04683315

Phase 2, Recruiting

Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors

for
Head and Neck Squamous Cell Carcinoma,
Location: Boston MA, Providence RI, New York NY, Montreal,
Sponsor: Bicara Therapeutics

Sex: All

Age: 18+

Code: NCT04429542

Phase 1, Recruiting

Pancreatic Cancer & Surgical Resection

for
Pancreas Cancer
Location: Dallas TX
Sponsor: Methodist Health System

Sex: All

Age: 18+

Code: NCT05170802

Recruiting

Repurposing Riluzole for Cancer-Related Cognitive Impairment: A Pilot Trial

for
Breast Cancer, Sarcoma, Gastric Cancer, Lung Cancer,
Location: Orange CA
Sponsor: University of California, Irvine

Sex: All

Age: 18+

Code: NCT06580002

Phase 2, Recruiting

Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer

for
Metastatic Colorectal Cancer, Metastatic Pancreatic Cancer,
Location: Bethesda MD
Sponsor: National Cancer Institute (NCI)

Sex: All

Age: 18 - 70+

Code: NCT01174121

Phase 2, Recruiting

Collection of Circulating Biomarkers in Pancreatic Cancer

for
Pancreas Cancer
Location: Philadelphia PA
Sponsor: Abramson Cancer Center at Penn Medicine

Sex: All

Age: 18+

Code: NCT05743049

Recruiting

What is pancreatic cancer?

The pancreas sits deep behind the stomach and makes both digestive enzymes and hormones like insulin. About 92 percent of pancreatic cancers start in the enzyme making cells, and this page is mostly about those. The other 8 percent are neuroendocrine tumors, which grow more slowly, have their own trials, and a five year survival of 72 percent against 8 percent. The pancreas gives no early warning. Jaundice, back pain, weight loss and new diabetes usually appear only after the cancer has grown or spread, and fewer than 20 percent of people can have surgery at diagnosis.

Smoking roughly doubles the risk, and type 2 diabetes, extra weight, chronic pancreatitis and family history raise it. About 10 percent of cases come from inherited mutations, so guidelines now recommend genetic testing for everyone diagnosed. That can change treatment and flag relatives who should be watched. The hope comes from biology. More than 90 percent of pancreatic cancers carry a KRAS mutation. That target was called undruggable for decades. Now several RAS inhibitors are in trials, with the first Phase 3 studies recruiting. Pancreatic cancer shares risk factors with type 2 diabetes and inherited genes with breast and ovarian cancer.

Article preview image

Our guide to new treatments for pancreatic cancer covers what has been approved and what is being tested.

Research Paving The Way To A New Treatment For Pancreatic Cancer

Types of pancreatic cancer clinical trials

Who can participate in pancreatic cancer clinical trials?

What causes pancreatic cancer?

The stages of pancreatic cancer, and why they matter for trials

How to enroll in a pancreatic cancer clinical trial